Investigators compared intra-articular microbial profiles and predicted metabolic pathways in patients with hip osteoarthritis and nonarthritic controls.
A systematic review of more than 2.3 million patients found that women and men had different patterns of postoperative complications and recovery, with age and implant strategy modifying observed differences.
In the phase 3 OPTIMA trial, the 10-mg/kg and 3-mg/kg doses reduced new heterotopic ossification lesions by 90% and 94%, respectively, compared with placebo at 56 weeks.
A synthesis of 21 studies provides reference values for evaluating clinically meaningful improvement following hip arthroscopy for femoroacetabular impingement.